12:00 AM
Feb 09, 2009
 |  BC Week In Review  |  Clinical News  |  Clinical Status

ISIS-SGLT2Rx: Phase I started

Isis began a double-blind, placebo-controlled, dose-escalation Phase I trial in 84 healthy volunteers.

Isis Pharmaceuticals...

Read the full 60 word article

User Sign in

Trial Subscription

Get a 4-week free trial subscription to BioCentury Week In Review

Article Purchase

$35 USD
More Info >